Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies

To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant <i>Klebsiella pneumoniae</i> and <i>Escherichia coli,</i> for bloodstream and urinary tract infections, respectively, and meticillin-resistant <i>Staphylococcus aureus</i> for surgical-site infections. Prioritised high-risk populations included surgical, haemato-oncological and transplant patients. Mortality and resource use were prioritised as health-economic outcomes. The importance of age-stratified data and inclusion of a non-infected comparator group were highlighted. This agenda provides guidance for future research to fill knowledge gaps and support data-driven selection of target pathogens and populations for new preventive and treatment strategies, specifically vaccines and mAbs, to effectively address the AMR burden in Europe. These research priorities are also relevant to improve the evidence base for future AMR burden estimates.

Authors

Institutions

Publication Details

Journal
Eurosurveillance
Published
2024-11-21
DOI
https://doi.org/10.2807/1560-7917.es.2024.29.47.2400212
Citations
7
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
2.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies

Diletta Pezzani, Andreas Kronenberg, Julie V. Robotham, Andrew J. Stewardson et al.
7 citations
Eurosurveillance
Antibiotic Use and Resistance
2.09
article

Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies

Diletta Pezzani, Andreas Kronenberg, Julie V. Robotham, Andrew J. Stewardson, Luigia Scudeller, Alessandro Cassini, Nasreen Hassoun‐Kheir, Yehuda Carmeli, Mila Nu Nu Htay, Beryl Primrose Gladstone, Stephan Harbarth, Evelina Tacconelli, Michele Cecchini, Koen B. Pouwels, Jeroen Geurtsen, Mariana Guedes, Jesús Rodríguez‐Baño, Mical Paul, Venanzio Vella, Isabel Frost, Fabiana Arieti, Marlieke E.A. de Kraker, Rhys Kingston, Francis Drobniewski, Nuno Rocha-Pereira
article en
7 citations

Abstract

To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant <i>Klebsiella pneumoniae</i> and <i>Escherichia coli,</i> for bloodstream and urinary tract infections, respectively, and meticillin-resistant <i>Staphylococcus aureus</i> for surgical-site infections. Prioritised high-risk populations included surgical, haemato-oncological and transplant patients. Mortality and resource use were prioritised as health-economic outcomes. The importance of age-stratified data and inclusion of a non-infected comparator group were highlighted. This agenda provides guidance for future research to fill knowledge gaps and support data-driven selection of target pathogens and populations for new preventive and treatment strategies, specifically vaccines and mAbs, to effectively address the AMR burden in Europe. These research priorities are also relevant to improve the evidence base for future AMR burden estimates.

EurosurveillanceVol. 29(47)
AstraZeneca (United Kingdom) (GB), University of Bern (CH), University of Verona (IT), Organisation de Coopération et de Développement Economiques (FR), Tel Aviv University (IL), Technion – Israel Institute of Technology (IL), Universidade do Porto (PT), Rambam Health Care Campus (IL), Instituto de Salud Carlos III (ES), The Alfred Hospital (AU), Hospital de São João (PT), University of Oxford (GB), Hospital Universitario Virgen Macarena (ES), Human Vaccines Project Europe (NL), University Hospital of Geneva (CH), Azienda USL di Bologna (IT), Manipal University College Malaysia (MY), University Children's Hospital Tübingen (DE), Instituto de Biomedicina de Sevilla (ES), Janssen (Netherlands) (NL), UK Health Security Agency (GB), Imperial College London (GB), Monash University (AU)
World Health Organization, Hôpitaux Universitaires de Genève, Università degli Studi di Verona
Openalex Percentile: Top 8%
Antibiotic Use and Resistance
2.09
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.